Sutro Biopharma shares rise on BofA Buy rating, $12 target

May 8, 2024 · The initiation of coverage by BofA Securities with a Buy rating and a $12 price target reflects confidence in Sutro Biopharma's strategic direction and the clinical development …

$12
OFF

Sutro Biopharma Shares Rise On BofA Buy Rating, $12 Target

2 weeks from now

May 8, 2024 · The initiation of coverage by BofA Securities with a Buy rating and a $12 price target reflects confidence in Sutro Biopharma's strategic direction and the clinical development …

investing.com

$12.00
OFF

BofA Maintains Buy Rating On Sutro Shares - Investing.com

2 weeks from now

Oct 11, 2024 · BofA Securities has kept its Buy rating and $12.00 price target for Sutro Biopharma (NASDAQ: NASDAQ: STRO), a clinical-stage drug discovery, development, and …

investing.com

$12.00
OFF

BofA Maintains Buy Rating On Sutro Shares - Investing.com Canada

2 weeks from now

Oct 11, 2024 · BofA Securities has kept its Buy rating and $12.00 price target for Sutro Biopharma (NASDAQ: NASDAQ: STRO), a clinical-stage drug discovery, development, and …

investing.com

$8
OFF

BofA Securities Starts Sutro Biopharma With Buy Rating

2 weeks from now

May 8, 2024 · -- Sutro Biopharma has an average rating of buy and price targets ranging from $8 to $20, according to analysts polled by Capital IQ. Price: 4.5200, Change: +0.27, Percent …

marketscreener.com

$8
OFF

BofA Securities Starts Sutro Biopharma With Buy Rating

2 weeks from now

-- Sutro Biopharma has an average rating of buy and price targets ranging from $8 to $20, according to analysts polled by Capital IQ. Price: 4.5200, Change: +0.27, Percent Change: …

marketscreener.com

$12.00
OFF

Buy Rating For Sutro Biopharma Backed By Promising Luvelta …

2 weeks from now

Sep 16, 2024 · Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sutro Biopharma (STRO – Research Report) yesterday and set a price target of $12.00.. …

businessinsider.com

$12
OFF

Sutro Biopharma Shares Rise On BofA Buy Rating, $12 Target

2 weeks from now

May 8, 2024 · Sutro Biopharma shares rise on BofA Buy rating, $12 target

investing.com

$12
OFF

Sutro Biopharma Shares Rise On BofA Buy Rating, $12 Target

2 weeks from now

May 8, 2024 · Sutro Biopharma shares rise on BofA Buy rating, $12 target

investing.com

$11
OFF

Sutro Biopharma, Inc.: Target Price Consensus And Analysts ...

2 weeks from now

Jan 8, 2025 · BofA Securities Starts Sutro Biopharma With Buy Rating 24-05-08: MT Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight …

marketscreener.com

$17.00
OFF

Sutro Biopharma’s Promising Market Expansion And Financial …

2 weeks from now

Nov 14, 2024 · JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00.. Reni Benjamin has given …

businessinsider.com

FAQs about Sutro Biopharma shares rise on BofA Buy rating, $12 target Coupon?

What is BofA's price objective for Sutro Biopharma (Stro)?

BofA set its price objective for the stock at $12. BofA has initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a buy rating, citing the potential of its ovarian cancer drug candidate luvelta. ...

Should you buy Sutro Biopharma (Stro – research report)?

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00. Reni Benjamin has given his Buy rating due to a combination of factors that highlight Sutro Biopharma’s promising prospects. ...

Who is Sutro Biopharma?

Begin your TipRanks Premium journey today. Sutro Biopharma (STRO) Company Description: Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. ...

Why did Reni Benjamin buy Sutro Biopharma?

Reni Benjamin has given his Buy rating due to a combination of factors that highlight Sutro Biopharma’s promising prospects. The company has demonstrated progress through its strategic expansion of luvelta into the NSCLC space, which signifies its potential to capture a broader market. ...